Selective OX1R antagonists target reward/metabolic imbalance in addiction-linked obesity, while agonists (e.g., orexin-A mimetics) could treat narcolepsy-associated IR by enhancing muscle uptake. The gene discussed is HCRT; the disease is obesity due to melanocortin 4 receptor deficiency.